Tango Therapeutics Management
Management criteria checks 3/4
Tango Therapeutics' CEO is Barbara Weber, appointed in Mar 2017, has a tenure of 7.08 years. total yearly compensation is $4.68M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 1.3% of the company’s shares, worth $10.18M. The average tenure of the management team and the board of directors is 2.7 years and 3.3 years respectively.
Key information
Barbara Weber
Chief executive officer
US$4.7m
Total compensation
| CEO salary percentage | 12.3% |
| CEO tenure | 7.1yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2.7yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%
Mar 19
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans
Mar 06Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk
Jan 08Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)
Aug 12Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?
May 10Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer
Oct 20Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth
Oct 05Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 13Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M
Aug 10We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn
May 28We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow
Jan 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$107m |
| Mar 31 2023 | n/a | n/a | -US$111m |
| Dec 31 2022 | US$5m | US$575k | -US$108m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$92m |
| Mar 31 2022 | n/a | n/a | -US$71m |
| Dec 31 2021 | US$12m | US$514k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$958k | US$492k | -US$52m |
Compensation vs Market: Barbara's total compensation ($USD4.68M) is above average for companies of similar size in the US market ($USD3.44M).
Compensation vs Earnings: Barbara's compensation has been consistent with company performance over the past year.
CEO
Barbara Weber (65 yo)
7.1yrs
Tenure
US$4,681,787
Compensation
Dr. Barbara L. Weber, M.D., has been the President and Chief Executive Officer of Tango Therapeutics Inc., since March 2017 and serves as Director and also served as Chairperson. Dr. Weber serves as a Dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.1yrs | US$4.68m | 1.3% $ 10.2m | |
| Chief Financial Officer | 7.5yrs | US$1.52m | 0.067% $ 521.1k | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Chief Legal Officer | 2.7yrs | no data | 0.041% $ 322.4k | |
| Vice President of Human Resources | 4yrs | no data | no data | |
| Head of Chemistry | 2.3yrs | no data | no data | |
| President of Research & Development | 1.2yrs | no data | 0.018% $ 137.1k |
2.7yrs
Average Tenure
54yo
Average Age
Experienced Management: TNGX's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$4.68m | 1.3% $ 10.2m | |
| Founder & Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Founder & Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Chairman | 7.3yrs | US$239.28k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$209.28k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 3.1yrs | US$215.78k | 0% $ 0 | |
| Independent Director | 5.6yrs | US$206.78k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
61yo
Average Age
Experienced Board: TNGX's board of directors are considered experienced (3.3 years average tenure).